IVERIC bio, Inc. (ISEE) Stock Analysis

IVERIC bio, Inc. (ISEE) Healthcare & Pipeline Overview

IVERIC bio, Inc. specializes in developing novel treatments for retinal diseases, with a focus on age-related and orphan inherited conditions. Their lead candidate, Zimura, targets geographic atrophy secondary to dry age-related macular degeneration, positioning them in the competitive biotechnology sector.

What Is the Investment Thesis for ISEE?

Positive results from the GATHER2 Phase 3 clinical trial could serve as a major catalyst, driving significant shareholder value. The company's focus on orphan inherited retinal diseases (IRDs) provides additional growth opportunities, leveraging the potential for accelerated regulatory pathways and market exclusivity. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other companies developing therapies for retinal diseases. With a market capitalization of $5.51B and a beta of 1.10, IVERIC bio represents a high-growth, high-risk investment opportunity within the biotechnology sector.

Based on FMP financials and quantitative analysis

ISEE Key Highlights

Zimura is in Phase 3 clinical trial (GATHER2) for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

• STAR (OPH2005) is in Phase 2b clinical trial for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1).
• IVERIC bio has a market capitalization of $5.51B.
• The company's pipeline includes IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor for GA and other age-related retinal diseases.
• IVERIC bio focuses on both age-related macular degeneration (AMD) and orphan inherited retinal diseases (IRDs).

Who Are ISEE's Competitors?

ISEE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ISEE's Key Strengths?

Strong pipeline of product candidates targeting retinal diseases.

• Lead product candidate, Zimura, has shown promising clinical results.
• Focus on both age-related and orphan inherited retinal diseases.
• Experienced management team with expertise in drug development and commercialization.

What Are ISEE's Weaknesses?

Reliance on the success of Zimura.

• High cash burn rate associated with clinical trials.
• Limited commercial infrastructure.
• Competition from larger pharmaceutical companies.

What Could Drive ISEE Stock Higher?

ISEE catalyst: Results from the GATHER2 Phase 3 clinical trial of Zimura for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

• Enrollment and progress in the Phase 2b clinical trial of STAR (OPH2005) for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1).
• Advancement of IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, through preclinical and clinical development.
• Potential for strategic partnerships or acquisitions to expand the company's pipeline and market reach.

What Are the Key Risks for ISEE?

Negative return on equity (-39.3%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $7.6M recently.
• Clinical trial failures for Zimura or other product candidates.
• Regulatory setbacks in obtaining approval for Zimura or other product candidates.
• Competition from other companies developing therapies for retinal diseases.
• Patent challenges to the company's intellectual property.
• High cash burn rate associated with clinical trials and research and development activities.

What Are the Growth Opportunities for ISEE?

• Expansion of Zimura into Additional Indications: IVERIC bio has the opportunity to expand the use of Zimura beyond geographic atrophy (GA) to treat other complement-mediated retinal diseases. This could significantly increase the addressable market for Zimura and drive revenue growth. The market size for complement-mediated retinal diseases is estimated to be substantial, with potential for multi-billion dollar sales. Timeline for expansion would depend on clinical trial results and regulatory approvals.
• Advancement of STAR (OPH2005) for LCA10 and STGD1: The successful development and commercialization of STAR (OPH2005) for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1) represents a significant growth opportunity. These are orphan inherited retinal diseases with limited treatment options, offering the potential for accelerated regulatory pathways and premium pricing. The market size for LCA10 and STGD1 treatments is estimated to be in the hundreds of millions of dollars.
• Development of IC-500 for GA and Other Age-Related Retinal Diseases: IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, has the potential to address a broader range of age-related retinal diseases beyond GA. This could significantly expand IVERIC bio's market reach and revenue potential. The market for age-related retinal disease treatments is substantial and growing, driven by an aging global population.
• Strategic Partnerships and Acquisitions: IVERIC bio could pursue strategic partnerships or acquisitions to expand its pipeline, access new technologies, or enter new geographic markets. This could accelerate growth and diversify the company's revenue streams. The biotechnology industry is characterized by frequent M&A activity, offering numerous opportunities for IVERIC bio to enhance its competitive position.
• Geographic Expansion: IVERIC bio has the opportunity to expand its commercial operations beyond the United States to international markets. This could significantly increase the company's revenue potential and market share. The global market for retinal disease treatments is substantial, with significant growth opportunities in Europe and Asia.

What Are ISEE's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Specialized expertise in retinal disease research and development.
• Established clinical trial infrastructure and regulatory expertise.
• Strong relationships with key opinion leaders in the ophthalmology field.

What Does ISEE Do?

IVERIC bio, Inc., founded in 2007 and headquartered in Parsippany, New Jersey, is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for retinal diseases. The company focuses on both age-related macular degeneration (AMD) and a range of orphan inherited retinal diseases (IRDs). IVERIC bio's lead product candidate is Zimura, an inhibitor of complement factor C5, which is being developed for the treatment of geographic atrophy (GA) secondary to dry AMD. Zimura has undergone Phase 2/3 (GATHER1) and is currently in Phase 3 (GATHER2) clinical trials. Beyond Zimura, IVERIC bio has a pipeline of additional product candidates, including STAR (OPH2005) for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1), currently in Phase 2b clinical trial. They also have IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor for GA, IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200 for IRDs associated with mutations in the BEST1 gene. The company also has discovery and research programs targeting LCA10, STGD1, and usher syndrome type 2A-Related IRDs. Formerly known as Ophthotech Corporation, IVERIC bio changed its name in April 2019 to reflect its expanded focus and pipeline.

What Products and Services Does ISEE Offer?

• Discovers and develops novel treatments for retinal diseases.
• Focuses on age-related macular degeneration (AMD) and orphan inherited retinal diseases (IRDs).
• Develops Zimura, an inhibitor of complement factor C5 for geographic atrophy (GA).
• Develops STAR (OPH2005) for Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1).
• Develops IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor for GA and other age-related retinal diseases.
• Conducts discovery and research programs for LCA10, STGD1, and usher syndrome type 2A-Related IRDs.

How Does ISEE Make Money?

• Develops and patents novel therapeutic candidates for retinal diseases.
• Conducts preclinical and clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA and EMA.
• Commercializes approved products through its own sales force or partnerships.

What Industry Does ISEE Operate In?

The biotechnology industry is characterized by high growth potential driven by innovation and unmet medical needs, particularly in areas like retinal diseases. The market for AMD treatments is substantial and growing, fueled by an aging global population. IVERIC bio operates in a competitive landscape that includes companies like LHCG: LHC Group, Inc., MRTX: Mirati Therapeutics, Inc., and CBAY: CymaBay Therapeutics, all vying for market share in various therapeutic areas. The success of IVERIC bio depends on its ability to navigate regulatory hurdles, demonstrate clinical efficacy, and secure market access for its products.

Who Are ISEE's Key Customers?

• Patients with age-related macular degeneration (AMD).
• Patients with orphan inherited retinal diseases (IRDs).
• Ophthalmologists and retinal specialists.
• Hospitals and clinics.

Company Profile

IVERIC bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Parsippany, US. The company is led by CEO Glenn P. Sblendorio. ISEE has traded publicly since 2013.

How IVERIC bio, Inc. Is Valued

IVERIC bio, Inc. carries a market capitalization of $5.51B, placing it in the mid-cap category.

Return on equity for IVERIC bio, Inc. stands at -39.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -26.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.6%, the inverse of the P/E and a quick read on earnings relative to price.

IVERIC bio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 22.04 places it in the safe zone, indicating low near-term bankruptcy risk.

The most recent 12 insider filings for IVERIC bio, Inc. break down as 12 sales and 0 purchases. On net that is roughly 650K shares disposed (about $7.6M), a signal worth weighing alongside the fundamentals.

ISEE Financials

ISEE Latest News

ISEE Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources